Abstract
In this multicenter, double-blind study, the antihypertensive efficacy and safety of irbesartan were compared with those of atenolol in patients with mild-to-moderate hypertension. Following a 4- to 5-week placebo lead-in period, 231 patients with seated diastolic blood pressure (SeDBP) 95-110 mmHg were randomized to irbesartan 75 mg or atenolol 50 mg once daily for 24 weeks. Doses were doubled at Week 6 for SeDBP > or = 90 mmHg. At Week 12, or anytime thereafter, doses were doubled for SeDBP > or = 90 mmHg if not done at Week 6, and hydrochlorothiazide and then nifedipine were added. Efficacy was determined by change from baseline in blood pressure and by therapeutic response rates. Safety was assessed by monitoring adverse events (AEs). Both treatments significantly lowered blood pressure from baseline. There were no significant differences between treatment groups with respect to blood pressure changes or therapeutic response. Atenolol significantly reduced seated heart rate compared with irbesartan at Week 12. The incidences of serious AEs and discontinuations due to AEs were approximately twice as high in the atenolol group compared with the irbesartan group. Thus, in comparison to atenolol, irbesartan < or = 150 mg provid...Continue Reading
References
Jan 1, 1995·Hypertension·A H van den MeirackerA J Man In 't Veld
Jul 1, 1994·American Journal of Hypertension·A Zanchetti
Mar 1, 1994·Medical Care·J S McCombsD A Sclar
Nov 1, 1993·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·K E Bernstein, B C Berk
Citations
Jul 24, 2001·Blood Pressure. Supplement·G Mancia
Oct 25, 2003·Journal of Cardiovascular Pharmacology·Carlo GaudioFrancesco Fedele
Nov 5, 2003·Blood Pressure·Lindon M H WingDanielle Molloy
Mar 20, 2004·Expert Review of Cardiovascular Therapy·Bernard Waeber, Michel Burnier
Feb 24, 2005·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Jean-Philippe BaguetPascal Auquier
Jul 18, 2008·Clinical and Experimental Hypertension : CHE·Luis M Ruilope, Julian Segura
Jul 16, 2009·Expert Opinion on Pharmacotherapy·Peter BramlageCaroline Hacker
Jul 27, 1999·Journal of Hypertension·W H Birkenhäger, P W de Leeuw
Dec 24, 2005·The Journal of International Medical Research·J M Neutel, D Smith
Mar 13, 2002·Clinical Pharmacokinetics·Chantal CsajkaJérôme Biollaz
Oct 4, 2005·Current Medical Research and Opinion·F StrutzW D Paar
Aug 9, 2003·Expert Opinion on Drug Safety·Neil Shusterman
Dec 24, 2005·Cardiology in Review·Mark J Eisenberg, Laura C Gioia
Jul 17, 2008·Drugs·Katherine F Croom, Greg L Plosker
Aug 1, 2002·Journal of Human Hypertension·J HasfordW R Simons
Feb 15, 2001·Circulation·M Burnier
Jun 14, 2001·Journal of Hypertension·K MalmqvistJ Ostergern
Jul 5, 2005·Expert Opinion on Investigational Drugs·C I Johnston
Mar 15, 2001·Blood Pressure Monitoring·J M Neutel
Apr 23, 2004·Drugs·Katherine F CroomCaroline M Perry
Nov 3, 2005·The International Journal of Cardiovascular Imaging·Nearchos S NearchouPanagiotis D Skoufas
Jun 14, 2000·Drugs·A MarkhamB Jarvis